**No hantavirus vaccine is positioned for regulatory approval or widespread availability by the end of 2026, aligning with the market’s 94.5% implied probability on “No.”** Multiple candidates, including Moderna’s mRNA platform with Korea University and UTMB’s single-dose Andes-focused mRNA constructs, remain in preclinical or early Phase 1 stages as of mid-2026, with only animal protection data available and no completed large-scale human efficacy trials. Existing inactivated vaccines are limited to specific strains in China and South Korea and lack approval in the US or EU. Recent outbreaks, such as the Andes strain on the MV Hondius cruise ship, have heightened attention but have not accelerated any candidate past early development or secured emergency-use pathways. Standard vaccine timelines—often 8–15 years from preclinical work to licensure—plus challenges in conducting Phase 3 trials for a rare disease with dispersed cases reinforce the current trader consensus, though an unexpected surge in funding or breakthrough regulatory designation could theoretically shift timelines.
Ringkasan eksperimental yang dihasilkan AI dengan referensi data Polymarket. Ini bukan saran trading dan tidak berperan dalam bagaimana pasar ini diselesaikan. · DiperbaruiHantavirus vaccine in 2026?
Hantavirus vaccine in 2026?
6% peluang
$131,745 Vol.
$131,745 Vol.
Dec 31, 2026
6% peluang
$131,745 Vol.
$131,745 Vol.
Dec 31, 2026
This market will resolve to "Yes" if any vaccine intended for humans and inoculating against Hantavirus (including Hantavirus Pulmonary Syndrome (HPS) or Hemorrhagic Fever with Renal Syndrome (HFRS)) receives full approval from the U.S. Food and Drug Administration between market creation and December 31, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No".
The primary resolution source for this market will be official information from the FDA, including its list of approved vaccines (https://www.fda.gov/vaccines-blood-biologics/vaccines/vaccines-licensed-use-united-states), however a consensus of credible reporting may also be used.**No hantavirus vaccine is positioned for regulatory approval or widespread availability by the end of 2026, aligning with the market’s 94.5% implied probability on “No.”** Multiple candidates, including Moderna’s mRNA platform with Korea University and UTMB’s single-dose Andes-focused mRNA constructs, remain in preclinical or early Phase 1 stages as of mid-2026, with only animal protection data available and no completed large-scale human efficacy trials. Existing inactivated vaccines are limited to specific strains in China and South Korea and lack approval in the US or EU. Recent outbreaks, such as the Andes strain on the MV Hondius cruise ship, have heightened attention but have not accelerated any candidate past early development or secured emergency-use pathways. Standard vaccine timelines—often 8–15 years from preclinical work to licensure—plus challenges in conducting Phase 3 trials for a rare disease with dispersed cases reinforce the current trader consensus, though an unexpected surge in funding or breakthrough regulatory designation could theoretically shift timelines.
This market will resolve to "Yes" if any vaccine intended for humans and inoculating against Hantavirus (including Hantavirus Pulmonary Syndrome (HPS) or Hemorrhagic Fever with Renal Syndrome (HFRS)) receives full approval from the U.S. Food and Drug Administration between market creation and December 31, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No".
The primary resolution source for this market will be official information from the FDA, including its list of approved vaccines (https://www.fda.gov/vaccines-blood-biologics/vaccines/vaccines-licensed-use-united-states), however a consensus of credible reporting may also be used.
The primary resolution source for this market will be official information from the FDA, including its list of approved vaccines (https://www.fda.gov/vaccines-blood-biologics/vaccines/vaccines-licensed-use-united-states), however a consensus of credible reporting may also be used.
Pasar Dibuka: May 4, 2026, 10:39 AM ET
Volume
$131,745Tanggal Berakhir
Jan 1, 2027Pasar Dibuka
May 4, 2026, 10:39 AM ETResolver
0x65070BE91...This market will resolve to "Yes" if any vaccine intended for humans and inoculating against Hantavirus (including Hantavirus Pulmonary Syndrome (HPS) or Hemorrhagic Fever with Renal Syndrome (HFRS)) receives full approval from the U.S. Food and Drug Administration between market creation and December 31, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No".
The primary resolution source for this market will be official information from the FDA, including its list of approved vaccines (https://www.fda.gov/vaccines-blood-biologics/vaccines/vaccines-licensed-use-united-states), however a consensus of credible reporting may also be used.**No hantavirus vaccine is positioned for regulatory approval or widespread availability by the end of 2026, aligning with the market’s 94.5% implied probability on “No.”** Multiple candidates, including Moderna’s mRNA platform with Korea University and UTMB’s single-dose Andes-focused mRNA constructs, remain in preclinical or early Phase 1 stages as of mid-2026, with only animal protection data available and no completed large-scale human efficacy trials. Existing inactivated vaccines are limited to specific strains in China and South Korea and lack approval in the US or EU. Recent outbreaks, such as the Andes strain on the MV Hondius cruise ship, have heightened attention but have not accelerated any candidate past early development or secured emergency-use pathways. Standard vaccine timelines—often 8–15 years from preclinical work to licensure—plus challenges in conducting Phase 3 trials for a rare disease with dispersed cases reinforce the current trader consensus, though an unexpected surge in funding or breakthrough regulatory designation could theoretically shift timelines.
This market will resolve to "Yes" if any vaccine intended for humans and inoculating against Hantavirus (including Hantavirus Pulmonary Syndrome (HPS) or Hemorrhagic Fever with Renal Syndrome (HFRS)) receives full approval from the U.S. Food and Drug Administration between market creation and December 31, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No".
The primary resolution source for this market will be official information from the FDA, including its list of approved vaccines (https://www.fda.gov/vaccines-blood-biologics/vaccines/vaccines-licensed-use-united-states), however a consensus of credible reporting may also be used.
The primary resolution source for this market will be official information from the FDA, including its list of approved vaccines (https://www.fda.gov/vaccines-blood-biologics/vaccines/vaccines-licensed-use-united-states), however a consensus of credible reporting may also be used.
Volume
$131,745Tanggal Berakhir
Jan 1, 2027Pasar Dibuka
May 4, 2026, 10:39 AM ETResolver
0x65070BE91...**No hantavirus vaccine is positioned for regulatory approval or widespread availability by the end of 2026, aligning with the market’s 94.5% implied probability on “No.”** Multiple candidates, including Moderna’s mRNA platform with Korea University and UTMB’s single-dose Andes-focused mRNA constructs, remain in preclinical or early Phase 1 stages as of mid-2026, with only animal protection data available and no completed large-scale human efficacy trials. Existing inactivated vaccines are limited to specific strains in China and South Korea and lack approval in the US or EU. Recent outbreaks, such as the Andes strain on the MV Hondius cruise ship, have heightened attention but have not accelerated any candidate past early development or secured emergency-use pathways. Standard vaccine timelines—often 8–15 years from preclinical work to licensure—plus challenges in conducting Phase 3 trials for a rare disease with dispersed cases reinforce the current trader consensus, though an unexpected surge in funding or breakthrough regulatory designation could theoretically shift timelines.
Ringkasan eksperimental yang dihasilkan AI dengan referensi data Polymarket. Ini bukan saran trading dan tidak berperan dalam bagaimana pasar ini diselesaikan. · Diperbarui
Hati-hati dengan link eksternal.
Hati-hati dengan link eksternal.
Pertanyaan yang Sering Diajukan